Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Anti-epileptic Drugs for Pediatrics Market 2018, Forecast to 2023

Publisher Name :
Date: 03-Jan-2019
No. of pages: 129

Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Depending on the area of the brain obstructed by seizures, these are categorized into generalized seizures and partial seizures. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Depending on their severity, seizures are termed as mild seizures and stronger seizures. Mild seizures are difficult to diagnose, as these last for only a few seconds. Stronger seizures may last for a few seconds to a few or several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.

Scope of the Report:

This report focuses on the Anti-epileptic Drugs for Pediatrics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for Anti-epileptic Drugs for Pediatrics is expected to grow at a CAGR of roughly 7.3% over the next five years, will reach 1270 million US$ in 2023, from 830 million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

- Mylan N.V

- Cephalon, Inc

- GlaxoSmithKline plc

- Janssen Pharmaceuticals

- Novartis AG

- Pfizer, Inc

- Sanofi S.A

- UCB Pharma Limited

- Sunovion Pharmaceuticals Limited

- Valeant Pharmaceuticals International, Inc

- Zogenix

- GW Pharmaceuticals

- Insys

- Zynerba

Market Segment by Regions, regional analysis covers

- North America (United States, Canada and Mexico)

- Europe (Germany, France, UK, Russia and Italy)

- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

- South America (Brazil, Argentina, Colombia etc.)

- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

- 1st generation

- 2nd generation

- 3rd generation

Market Segment by Applications, can be divided into

- Hospitals

- Retail pharmacies

- Online pharmacies

There are 15 Chapters to deeply display the global Anti-epileptic Drugs for Pediatrics market.

Chapter 1, to describe Anti-epileptic Drugs for Pediatrics Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Anti-epileptic Drugs for Pediatrics, with sales, revenue, and price of Anti-epileptic Drugs for Pediatrics, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Anti-epileptic Drugs for Pediatrics, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Anti-epileptic Drugs for Pediatrics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Anti-epileptic Drugs for Pediatrics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Anti-epileptic Drugs for Pediatrics Market 2018, Forecast to 2023

Table of Contents

1 Market Overview
1.1 Anti-epileptic Drugs for Pediatrics Introduction
1.2 Market Analysis by Type
1.2.1 1st generation
1.2.2 2nd generation
1.2.3 3rd generation
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Retail pharmacies
1.3.3 Online pharmacies
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Mylan N.V
2.1.1 Business Overview
2.1.1.1 Mylan N.V Description
2.1.1.2 Mylan N.V Headquarter, Main Business and Finance Overview
2.1.2 Mylan N.V Anti-epileptic Drugs for Pediatrics Product Introduction
2.1.2.1 Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
2.1.2.2 Anti-epileptic Drugs for Pediatrics Product Information
2.1.3 Mylan N.V Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.1 Mylan N.V Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.2 Global Mylan N.V Anti-epileptic Drugs for Pediatrics Market Share in 2017
2.2 Cephalon, Inc
2.2.1 Business Overview
2.2.1.1 Cephalon, Inc Description
2.2.1.2 Cephalon, Inc Headquarter, Main Business and Finance Overview
2.2.2 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Product Introduction
2.2.2.1 Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
2.2.2.2 Anti-epileptic Drugs for Pediatrics Product Information
2.2.3 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.1 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.2 Global Cephalon, Inc Anti-epileptic Drugs for Pediatrics Market Share in 2017
2.3 GlaxoSmithKline plc
2.3.1 Business Overview
2.3.1.1 GlaxoSmithKline plc Description
2.3.1.2 GlaxoSmithKline plc Headquarter, Main Business and Finance Overview
2.3.2 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Product Introduction
2.3.2.1 Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
2.3.2.2 Anti-epileptic Drugs for Pediatrics Product Information
2.3.3 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.1 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.2 Global GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Market Share in 2017
2.4 Janssen Pharmaceuticals
2.4.1 Business Overview
2.4.1.1 Janssen Pharmaceuticals Description
2.4.1.2 Janssen Pharmaceuticals Headquarter, Main Business and Finance Overview
2.4.2 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product Introduction
2.4.2.1 Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
2.4.2.2 Anti-epileptic Drugs for Pediatrics Product Information
2.4.3 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.1 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.2 Global Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Market Share in 2017
2.5 Novartis AG
2.5.1 Business Overview
2.5.1.1 Novartis AG Description
2.5.1.2 Novartis AG Headquarter, Main Business and Finance Overview
2.5.2 Novartis AG Anti-epileptic Drugs for Pediatrics Product Introduction
2.5.2.1 Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
2.5.2.2 Anti-epileptic Drugs for Pediatrics Product Information
2.5.3 Novartis AG Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.3.1 Novartis AG Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.3.2 Global Novartis AG Anti-epileptic Drugs for Pediatrics Market Share in 2017
2.6 Pfizer, Inc
2.6.1 Business Overview
2.6.1.1 Pfizer, Inc Description
2.6.1.2 Pfizer, Inc Headquarter, Main Business and Finance Overview
2.6.2 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Product Introduction
2.6.2.1 Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
2.6.2.2 Anti-epileptic Drugs for Pediatrics Product Information
2.6.3 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.3.1 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.3.2 Global Pfizer, Inc Anti-epileptic Drugs for Pediatrics Market Share in 2017
2.7 Sanofi S.A
2.7.1 Business Overview
2.7.1.1 Sanofi S.A Description
2.7.1.2 Sanofi S.A Headquarter, Main Business and Finance Overview
2.7.2 Sanofi S.A Anti-epileptic Drugs for Pediatrics Product Introduction
2.7.2.1 Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
2.7.2.2 Anti-epileptic Drugs for Pediatrics Product Information
2.7.3 Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.3.1 Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.3.2 Global Sanofi S.A Anti-epileptic Drugs for Pediatrics Market Share in 2017
2.8 UCB Pharma Limited
2.8.1 Business Overview
2.8.1.1 UCB Pharma Limited Description
2.8.1.2 UCB Pharma Limited Headquarter, Main Business and Finance Overview
2.8.2 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Product Introduction
2.8.2.1 Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
2.8.2.2 Anti-epileptic Drugs for Pediatrics Product Information
2.8.3 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.3.1 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.3.2 Global UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Market Share in 2017
2.9 Sunovion Pharmaceuticals Limited
2.9.1 Business Overview
2.9.1.1 Sunovion Pharmaceuticals Limited Description
2.9.1.2 Sunovion Pharmaceuticals Limited Headquarter, Main Business and Finance Overview
2.9.2 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Product Introduction
2.9.2.1 Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
2.9.2.2 Anti-epileptic Drugs for Pediatrics Product Information
2.9.3 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9.3.1 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9.3.2 Global Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Market Share in 2017
2.10 Valeant Pharmaceuticals International, Inc
2.10.1 Business Overview
2.10.1.1 Valeant Pharmaceuticals International, Inc Description
2.10.1.2 Valeant Pharmaceuticals International, Inc Headquarter, Main Business and Finance Overview
2.10.2 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Product Introduction
2.10.2.1 Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
2.10.2.2 Anti-epileptic Drugs for Pediatrics Product Information
2.10.3 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10.3.1 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10.3.2 Global Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Market Share in 2017
2.11 Zogenix
2.11.1 Business Overview
2.11.2 Zogenix Anti-epileptic Drugs for Pediatrics Product Introduction
2.11.3 Zogenix Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 GW Pharmaceuticals
2.12.1 Business Overview
2.12.2 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product Introduction
2.12.3 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Insys
2.13.1 Business Overview
2.13.2 Insys Anti-epileptic Drugs for Pediatrics Product Introduction
2.13.3 Insys Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Zynerba
2.14.1 Business Overview
2.14.2 Zynerba Anti-epileptic Drugs for Pediatrics Product Introduction
2.14.3 Zynerba Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Anti-epileptic Drugs for Pediatrics Market Competition, by Manufacturer
3.1 Global Anti-epileptic Drugs for Pediatrics Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Anti-epileptic Drugs for Pediatrics Revenue and Market Share by Manufacturer (2016-2017)
3.3 Global Anti-epileptic Drugs for Pediatrics Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Anti-epileptic Drugs for Pediatrics Manufacturer Market Share in 2017
3.4.2 Top 5 Anti-epileptic Drugs for Pediatrics Manufacturer Market Share in 2017
3.5 Market Competition Trend
4 Global Anti-epileptic Drugs for Pediatrics Market Analysis by Regions
4.1 Global Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Regions
4.1.1 Global Anti-epileptic Drugs for Pediatrics Sales by Regions (2013-2018)
4.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Regions (2013-2018)
4.2 North America Anti-epileptic Drugs for Pediatrics Sales, Revenue and Growth Rate (2013-2018)
4.3 Europe Anti-epileptic Drugs for Pediatrics Sales, Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Anti-epileptic Drugs for Pediatrics Sales, Revenue and Growth Rate (2013-2018)
4.5 South America Anti-epileptic Drugs for Pediatrics Sales, Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales, Revenue and Growth Rate (2013-2018)
5 North America Anti-epileptic Drugs for Pediatrics by Countries, Type, Application and Manufacturers
5.1 North America Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Countries
5.1.1 North America Anti-epileptic Drugs for Pediatrics Sales by Countries (2013-2018)
5.1.2 North America Anti-epileptic Drugs for Pediatrics Revenue by Countries (2013-2018)
5.1.3 United States Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
5.1.4 Canada Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
5.1.5 Mexico Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
5.2 North America Anti-epileptic Drugs for Pediatrics Sales and Revenue (Value) by Manufacturers (2016-2017)
5.2.1 North America Anti-epileptic Drugs for Pediatrics Sales by Manufacturers (2016-2017)
5.2.2 North America Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers (2016-2017)
5.3 North America Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Type (2013-2018)
5.3.1 North America Anti-epileptic Drugs for Pediatrics Sales and Sales Share by Type (2013-2018)
5.3.2 North America Anti-epileptic Drugs for Pediatrics Revenue and Revenue Share by Type (2013-2018)
5.4 North America Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Application (2013-2018)
5.4.1 North America Anti-epileptic Drugs for Pediatrics Sales and Sales Share by Application (2013-2018)
5.4.2 North America Anti-epileptic Drugs for Pediatrics Revenue and Revenue Share by Application (2013-2018)
6 Europe Anti-epileptic Drugs for Pediatrics by Countries, Type, Application and Manufacturers
6.1 Europe Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Countries
6.1.1 Europe Anti-epileptic Drugs for Pediatrics Sales by Countries (2013-2018)
6.1.2 Europe Anti-epileptic Drugs for Pediatrics Revenue by Countries (2013-2018)
6.1.3 Germany Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
6.1.4 UK Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
6.1.5 France Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
6.1.6 Russia Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
6.1.7 Italy Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
6.2 Europe Anti-epileptic Drugs for Pediatrics Sales and Revenue (Value) by Manufacturers (2016-2017)
6.2.1 Europe Anti-epileptic Drugs for Pediatrics Sales by Manufacturers (2016-2017)
6.2.2 Europe Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers (2016-2017)
6.3 Europe Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Type (2013-2018)
6.3.1 Europe Anti-epileptic Drugs for Pediatrics Sales and Sales Share by Type (2013-2018)
6.3.2 Europe Anti-epileptic Drugs for Pediatrics Revenue and Revenue Share by Type (2013-2018)
6.4 Europe Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Application (2013-2018)
6.4.1 Europe Anti-epileptic Drugs for Pediatrics Sales and Sales Share by Application (2013-2018)
6.4.2 Europe Anti-epileptic Drugs for Pediatrics Revenue and Revenue Share by Application (2013-2018)
7 Asia-Pacific Anti-epileptic Drugs for Pediatrics by Countries, Type, Application and Manufacturers
7.1 Asia-Pacific Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Anti-epileptic Drugs for Pediatrics Sales by Countries (2013-2018)
7.1.2 Asia-Pacific Anti-epileptic Drugs for Pediatrics Revenue by Countries (2013-2018)
7.1.3 China Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
7.1.4 Japan Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
7.1.5 Korea Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
7.1.6 India Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
7.1.7 Southeast Asia Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
7.2 Asia-Pacific Anti-epileptic Drugs for Pediatrics Sales and Revenue (Value) by Manufacturers (2016-2017)
7.2.1 Asia-Pacific Anti-epileptic Drugs for Pediatrics Sales by Manufacturers (2016-2017)
7.2.2 Asia-Pacific Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers (2016-2017)
7.3 Asia-Pacific Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Type (2013-2018)
7.3.1 Asia-Pacific Anti-epileptic Drugs for Pediatrics Sales and Sales Share by Type (2013-2018)
7.3.2 Asia-Pacific Anti-epileptic Drugs for Pediatrics Revenue and Revenue Share by Type (2013-2018)
7.4 Asia-Pacific Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Application (2013-2018)
7.4.1 Asia-Pacific Anti-epileptic Drugs for Pediatrics Sales and Sales Share by Application (2013-2018)
7.4.2 Asia-Pacific Anti-epileptic Drugs for Pediatrics Revenue and Revenue Share by Application (2013-2018)
8 South America Anti-epileptic Drugs for Pediatrics by Countries, Type, Application and Manufacturers
8.1 South America Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Countries
8.1.1 South America Anti-epileptic Drugs for Pediatrics Sales by Countries (2013-2018)
8.1.2 South America Anti-epileptic Drugs for Pediatrics Revenue by Countries (2013-2018)
8.1.3 Brazil Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
8.1.4 Argentina Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
8.1.5 Colombia Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
8.2 South America Anti-epileptic Drugs for Pediatrics Sales and Revenue (Value) by Manufacturers (2016-2017)
8.2.1 South America Anti-epileptic Drugs for Pediatrics Sales by Manufacturers (2016-2017)
8.2.2 South America Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers (2016-2017)
8.3 South America Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Type (2013-2018)
8.3.1 South America Anti-epileptic Drugs for Pediatrics Sales and Sales Share by Type (2013-2018)
8.3.2 South America Anti-epileptic Drugs for Pediatrics Revenue and Revenue Share by Type (2013-2018)
8.4 South America Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Application (2013-2018)
8.4.1 South America Anti-epileptic Drugs for Pediatrics Sales and Sales Share by Application (2013-2018)
8.4.2 South America Anti-epileptic Drugs for Pediatrics Revenue and Revenue Share by Application (2013-2018)
9 Middle East and Africa Anti-epileptic Drugs for Pediatrics by Countries, Type, Application and Manufacturers
9.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Countries (2013-2018)
9.1.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue by Countries (2013-2018)
9.1.3 Saudi Arabia Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
9.1.4 UAE Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
9.1.5 Egypt Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
9.1.6 Nigeria Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
9.1.7 South Africa Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
9.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales and Revenue (Value) by Manufacturers (2016-2017)
9.2.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Manufacturers (2016-2017)
9.2.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers (2016-2017)
9.3 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Type (2013-2018)
9.3.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales and Sales Share by Type (2013-2018)
9.3.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue and Revenue Share by Type (2013-2018)
9.4 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Application (2013-2018)
9.4.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales and Sales Share by Application (2013-2018)
9.4.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue and Revenue Share by Application (2013-2018)
10 Global Anti-epileptic Drugs for Pediatrics Market Segment by Type
10.1 Global Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Anti-epileptic Drugs for Pediatrics Sales and Market Share by Type (2013-2018)
10.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue and Market Share by Type (2013-2018)
10.2 1st generation Sales Growth and Price
10.2.1 Global 1st generation Sales Growth (2013-2018)
10.2.2 Global 1st generation Price (2013-2018)
10.3 2nd generation Sales Growth and Price
10.3.1 Global 2nd generation Sales Growth (2013-2018)
10.3.2 Global 2nd generation Price (2013-2018)
10.4 3rd generation Sales Growth and Price
10.4.1 Global 3rd generation Sales Growth (2013-2018)
10.4.2 Global 3rd generation Price (2013-2018)
11 Global Anti-epileptic Drugs for Pediatrics Market Segment by Application
11.1 Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Retail pharmacies Sales Growth (2013-2018)
11.4 Online pharmacies Sales Growth (2013-2018)
12 Anti-epileptic Drugs for Pediatrics Market Forecast (2018-2023)
12.1 Global Anti-epileptic Drugs for Pediatrics Sales, Revenue and Growth Rate (2018-2023)
12.2 Anti-epileptic Drugs for Pediatrics Market Forecast by Regions (2018-2023)
12.2.1 North America Anti-epileptic Drugs for Pediatrics Market Forecast (2018-2023)
12.2.2 Europe Anti-epileptic Drugs for Pediatrics Market Forecast (2018-2023)
12.2.3 Asia-Pacific Anti-epileptic Drugs for Pediatrics Market Forecast (2018-2023)
12.2.4 South America Anti-epileptic Drugs for Pediatrics Market Forecast (2018-2023)
12.2.5 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Forecast (2018-2023)
12.3 Anti-epileptic Drugs for Pediatrics Market Forecast by Type (2018-2023)
12.3.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Type (2018-2023)
12.3.2 Global Anti-epileptic Drugs for Pediatrics Market Share Forecast by Type (2018-2023)
12.4 Anti-epileptic Drugs for Pediatrics Market Forecast by Application (2018-2023)
12.4.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Application (2018-2023)
12.4.2 Global Anti-epileptic Drugs for Pediatrics Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source

List of Tables and Figures

Figure Anti-epileptic Drugs for Pediatrics Picture
Table Product Specifications of Anti-epileptic Drugs for Pediatrics
Figure Global Anti-epileptic Drugs for Pediatrics CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (USD Million)
Figure Global Anti-epileptic Drugs for Pediatrics CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (Sales)
Figure Global Sales Market Share of Anti-epileptic Drugs for Pediatrics by Types in 2017
Figure 1st generation Picture
Table Major Manufacturers of 1st generation
Figure 2nd generation Picture
Table Major Manufacturers of 2nd generation
Figure 3rd generation Picture
Table Major Manufacturers of 3rd generation
Figure Anti-epileptic Drugs for Pediatrics Sales Market Share by Applications in 2017
Figure Hospitals Picture
Figure Retail pharmacies Picture
Figure Online pharmacies Picture
Figure United States Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure Canada Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure Germany Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure France Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure UK Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure Russia Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure Italy Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure China Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure Japan Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure Korea Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure India Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria Anti-epileptic Drugs for Pediatrics Revenue (Value) and Growth Rate (2013-2023)
Table Mylan N.V Headquarter, Established, Main Business and Finance Overview (2017)
Table Mylan N.V Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
Table Mylan N.V Anti-epileptic Drugs for Pediatrics Product
Table Mylan N.V Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Mylan N.V Anti-epileptic Drugs for Pediatrics Sales Market Share in 2017
Figure Global Mylan N.V Anti-epileptic Drugs for Pediatrics Revenue Market Share in 2017
Table Cephalon, Inc Headquarter, Established, Main Business and Finance Overview (2017)
Table Cephalon, Inc Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
Table Cephalon, Inc Anti-epileptic Drugs for Pediatrics Product
Table Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales Market Share in 2017
Figure Global Cephalon, Inc Anti-epileptic Drugs for Pediatrics Revenue Market Share in 2017
Table GlaxoSmithKline plc Headquarter, Established, Main Business and Finance Overview (2017)
Table GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
Table GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Product
Table GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales Market Share in 2017
Figure Global GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Revenue Market Share in 2017
Table Janssen Pharmaceuticals Headquarter, Established, Main Business and Finance Overview (2017)
Table Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
Table Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Product
Table Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales Market Share in 2017
Figure Global Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Revenue Market Share in 2017
Table Novartis AG Headquarter, Established, Main Business and Finance Overview (2017)
Table Novartis AG Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
Table Novartis AG Anti-epileptic Drugs for Pediatrics Product
Table Novartis AG Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Novartis AG Anti-epileptic Drugs for Pediatrics Sales Market Share in 2017
Figure Global Novartis AG Anti-epileptic Drugs for Pediatrics Revenue Market Share in 2017
Table Pfizer, Inc Headquarter, Established, Main Business and Finance Overview (2017)
Table Pfizer, Inc Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
Table Pfizer, Inc Anti-epileptic Drugs for Pediatrics Product
Table Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales Market Share in 2017
Figure Global Pfizer, Inc Anti-epileptic Drugs for Pediatrics Revenue Market Share in 2017
Table Sanofi S.A Headquarter, Established, Main Business and Finance Overview (2017)
Table Sanofi S.A Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
Table Sanofi S.A Anti-epileptic Drugs for Pediatrics Product
Table Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales Market Share in 2017
Figure Global Sanofi S.A Anti-epileptic Drugs for Pediatrics Revenue Market Share in 2017
Table UCB Pharma Limited Headquarter, Established, Main Business and Finance Overview (2017)
Table UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
Table UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Product
Table UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales Market Share in 2017
Figure Global UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Revenue Market Share in 2017
Table Sunovion Pharmaceuticals Limited Headquarter, Established, Main Business and Finance Overview (2017)
Table Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Production Bases, Sales Regions and Major Competitors
Table Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Product
Table Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Sunovion Pharmaceuticals Limited Anti-epilept
  • Global Antioxidant Vitamins Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100
    The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
  • Global Clavulanate Potassium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
  • Global Amoxicillin Sodium Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84
    The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
  • Global Melatonin Supplements Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
  • Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
  • Global Sleeping Pills Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94
    The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Zinc Oral Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
  • Global Zinc Drops Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
  • Global Anti-Infectives Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78
    The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs